In this study, we conducted a comprehensive pan‐cancer analysis to delineate shared and cancer type‐specific molecular programs orchestrated by TP53/RB1 co‐alterations across diverse malignancies and to identify actionable therapeutic vulnerabilities associated with these alterations. Here, RB1 is linked to cancer.